The Impact of Elexacaftor-Tezacaftor-Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study
preprint
OA: closed
Abstract
Background: Elexacaftor-tezacaftor-ivacaftor (ETI) has significantly improved lung function and growth in people with cystic fibrosis (PwCF). However, its impact on CF hepatobiliary involvement (CFHBI) remains unclear. This study aims to investigate the impact of ETI on biochemical surrogates of CFHBI using a large population database. Methods: : This 1:1 retrospective cohort study utilized TriNetX, a de-identified multicenter database, and included patients aged 6-21 years with ICD-10 diagnostic codes for CF and prescribed pancreatic enzyme replacement therapy. ETI group (PwCF on ETI from 1/1/2020 to 1/1/2024) and non-ETI group (PwCF not on ETI seen from 1/1/2014 to 1/1/2018) were analyzed. Groups were matched using propensity scores, and statistical analyses were performed on TriNetX (significance set at p=0.05). Results: : There were 533 children with CF (CwCF) aged 6-12 years and 1,177 adolescents and young adults with CF aged 13-21 years in each cohort. In CwCF, the ETI group had significantly lower ALT (33 ± 44 U/L vs. 45 ± 57 U/L, p=0.003) and GGT levels (18 ± 20 U/L vs. 28 ± 51 U/L, p=0.004), as well as improved albumin and PT/INR compared to non-ETI group. In PwCF (13-21), the ETI group had significantly lower GGT (21 ± 26 U/L vs. 32 ± 63 U/L, p=0.002), and improved albumin and PT compared to non-ETI group, however indirect bilirubin was higher (0.7 ± 0.5 mg/dL vs. 0.3 ± 0.4 mg/dL, p<0.001). Conclusion: Our findings suggest that early ETI use is associated with improved liver enzymes, offering reassurance against widespread drug-induced liver injury. Long-term follow-up including imaging and biopsy when available, pre- and post-ETI, is needed to better assess the impact of ETI on CFHBI and advanced CF liver disease.
Full text
3,041 characters
· extracted from
oa-doi-fallback
· 2 sections
· click to expand
Abstract
Background: Elexacaftor-tezacaftor-ivacaftor (ETI) has significantly improved lung function and growth in people with cystic fibrosis (PwCF). However, its impact on CF hepatobiliary involvement (CFHBI) remains unclear. This study aims to investigate the impact of ETI on biochemical surrogates of CFHBI using a large population database. Methods: This 1:1 retrospective cohort study utilized TriNetX, a de-identified multicenter database, and included patients aged 6-21 years with ICD-10 diagnostic codes for CF and prescribed pancreatic enzyme replacement therapy. ETI group (PwCF on ETI from 1/1/2020 to 1/1/2024) and non-ETI group (PwCF not on ETI seen from 1/1/2014 to 1/1/2018) were analyzed. Groups were matched using propensity scores, and statistical analyses were performed on TriNetX (significance set at p=0.05). Results: There were 533 children with CF (CwCF) aged 6-12 years and 1,177 adolescents and young adults with CF aged 13-21 years in each cohort. In CwCF, the ETI group had significantly lower ALT (33 ± 44 U/L vs. 45 ± 57 U/L, p=0.003) and GGT levels (18 ± 20 U/L vs. 28 ± 51 U/L, p=0.004), as well as improved albumin and PT/INR compared to non-ETI group. In PwCF (13-21), the ETI group had significantly lower GGT (21 ± 26 U/L vs. 32 ± 63 U/L, p=0.002), and improved albumin and PT compared to non-ETI group, however indirect bilirubin was higher (0.7 ± 0.5 mg/dL vs. 0.3 ± 0.4 mg/dL, p<0.001). Conclusion: Our findings suggest that early ETI use is associated with improved liver enzymes, offering reassurance against widespread drug-induced liver injury. Long-term follow-up including imaging and biopsy when available, pre- and post-ETI, is needed to better assess the impact of ETI on CFHBI and advanced CF liver disease.
Supplementary Material
File (manuscript cf liver diseases.docx)
- Download
- 83.68 KB
Information & Authors
Information
Version history
Peer review timeline
Published
Pediatric Pulmonology
Version of Record18 Feb 2026Published
Copyright
This work is licensed under a Non Exclusive No Reuse License.
Keywords
Authors
Metrics & Citations
Metrics
Article Usage
239views
158downloads
Citations
Download citation
Sasha-Jane Abi-Aad, Athanasios Tsalatsanis, Michael Narkewicz, et al.
The Impact of Elexacaftor-Tezacaftor-Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study. Authorea. 10 July 2025.
DOI: https://doi.org/10.22541/au.175217262.23486396/v1
DOI: https://doi.org/10.22541/au.175217262.23486396/v1
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Ask this paper
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- europepmc
- last seen: 2026-05-20T01:45:00.602351+00:00